Physician profile
Bade Akintan
NPI 1831202167
$1,361.78
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $288 · 2021: $650.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $547.48 | 2019-2021 | |
| Janssen Biotech, INC. | $248.61 | 2019-2021 | |
| Pfizer INC. | $206.09 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $155.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $92.44 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.97 | 2019-2021 | |
| Teleflex LLC | $34.66 | 2021 | |
| Verity Pharmaceuticals INC. | $21.68 | 2021 | |
| Allergan, INC. | $14.38 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bade Akintan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.